One of the most significant challenges in cancer treatment is the development of drug resistance. Tumor cells can mutate, rendering first-generation TKIs ineffective. Next generation TKIs are engineered to target these mutations specifically. For example, Osimertinib is effective against non-small cell lung cancer (NSCLC) with the T790M mutation, a common resistance mutation to earlier TKIs like Erlotinib and Gefitinib.
